Company Profile - Aeglea BioTherapeutics Inc


Aeglea BioTherapeutics Inc (Aeglea) is a biotechnology company. The company develops and commercializes human enzymes for the treatment of cancer and rare genetic diseases. The company’s lead product pipeline includes pegzilarginase (AEB1102), is used for the treatment of arginase deficiency. It also develops AGLE-177, for treating classical homocystinuria, a rare disease cause due to hereditary genetic deficiency; AGLE-324, for treating cystinuria. Aeglea also provides enzyme solutions to treat diseases with unmet medical needs. The company works in partnership with research institutions, healthcare providers and pharmaceutical companies. It caters its products across the US and the UK. Aeglea is headquartered in Austin, Texas, the US.

Company info

Country (HQ): United States
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 10
Revenue (US$ m): 2 (2022)

Innovation ranking


Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking


Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd


Pharmaceuticals and Healthcare

Aeglea BioTherapeutics Inc

United States

Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers